MedTrace Logo

3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects

NCT03103295 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-05-11

No results posted yet for this study

Summary

This study investigates safety and efficacy of traumatic bone defects treatment with use of 3D tissue engineered bone equivalent (3D-TEBE).

The aim of this study is to evaluate 3D-TEBE transplantation as a safe and efficient treatment for patients with traumatic long bone defects of critical size.

Conditions

  • Bone Defects

Interventions

BIOLOGICAL

3D-Tissue Engineered Bone Equivalent

Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent

Sponsors & Collaborators

  • A.A. Partners, LLC

    lead OTHER

Principal Investigators

  • Volodymyr M. Oksymets, MD,PhD,DSci · LIMITED LIABILITY COMPANY "A.A. PARTNERS" (Medical company ilaya® ),

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-20
Primary Completion
2018-12-20
Completion
2018-12-20

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03103295 on ClinicalTrials.gov